CytoDyn Shares Exciting Results From Their Triple-Negative Breast Cancer Treatment Program with The Stock Day Podcast

from Stock Day Media · host Stock Day Media

The Stock Day Podcast welcomed CytoDyn (CYDY)(“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO of the Company, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Episode metadata supplied by the publisher feed · Published Dec 5, 2019

Embed this episode

Attribution link and audio player

Ready to play

CytoDyn Shares Exciting Results From Their Triple-Negative Breast Cancer Treatment Program with The Stock Day Podcast

0:00 9:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Stock Day Media?

This episode is 9 minutes long.

When was this Stock Day Media episode published?

This episode was published on December 5, 2019.

Can I download this Stock Day Media episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!